Abstract: The present invention relates to method for preventing, treating or alleviating a central nervous system (CNS) disorder using a non replicative lentivirus comprising a lentiviral genome comprising a nucleic acid sequence producing at least one functional miRNA, at least one functional shRNA and/or at least one functional siRNA, preferably derived from said shRNA, said miRNA, shRNA or siRNA being designed to silence the expression of a gene that encodes a protein of the astrocyte cytoskeleton. The present invention further relates to compositions and kits comprising such a lentivirus as well as to uses thereof.

Abstract: The invention relates to a method for production of neurons from cells of a cell line which may be differentiated to produce neurons in particular, whereby said cells are cultivated in spheres, preferably by exposing the same to growth factors, such as, for example, EGF (epidermal growth factor) and/or bFGF (basic fibroblast growth factor) or LIF (Leukemia Inhibitory Factor), in a given growth medium, the differentiation in said spheres is induced on forcing the same to adhere to a substrate, after removal of the growth factors EGF and/or bFGF or LIF, and cultivating the same in the growth medium for an appropriate duration. Said method is characterised in that cells of the human embryonic teratocarcinoma NT2 are used.

Abstract: The present invention relates to methods and compositions for delivering a nucleic acid to motor neurons administering the nucleic acid to muscle tissue. The invention relates to methods for treating pathologies of the nervous system, such as trauma and neurodegenerative diseases.

Abstract: The present invention relates to methods and compositions for delivering nucleic acids to motor neurons by administering the nucleic acids to muscle tissue. The invention relates to methods for treating pathologies of the nervous system, such as trauma and neurodegenerative diseases.

Abstract: The present invention relates to methods and compositions for delivering nucleic acids to motor neurons by administering the nucleic acids to muscle tissue. The invention relates to methods for treating pathologies of the nervous system, such as trauma and neurodegenerative diseases.

Abstract: A pharmaceutical composition conatining at least one C3-OH ether or fatty acid monoester of 7B-hydroxycholesterol selected from the group consisting of the ethers or esters of palmitic, oleic, hexenoic, decenoic and arachindonic acids or esters. The composition is useful as a cytotoxic agent for the treatment on cells having a high proliferative potential.

Abstract: The invention relates to pharmaceutical compositions for neuroprotection containing the compound (1S,2R) 1-[1-(2-thienyl)-2-alkylcyclohexyl]piperidine or (1S,2R) 1-[1-(2-furanyl)-2-alkylcyclohexyl]piperdine, or their pharmaceutically acceptable salts. The synthesis and method separation of racemic mixtures to provide pure enantiomers is presented. The compositions have use in the treatment of stroke, CNS trauma and Alzheimer's disease.

Abstract: The invention relates to substituted arylamines and heteroarylamines, their preparation process and the pharmaceutical composition containing them. Said substituted amine is in accordance with the formula: ##STR1## in which R.sup.1 and R.sup.2 are optionally substituted alkyl radicals or form with N an optionally substituted piperazine or piperidine cycle, R.sup.3 and R.sup.4 represent a hydrogen atom or an organic radical, Y represents CR.sup.6 or N and R.sup.5 is an optionally substituted benzothiophenyl, benzofuranyl or naphthyl radical.These amines can be used in pharmaceutical compositions for the treatment of nervous depression or for stimulating vigilance.

Abstract: The invention relates to pharmaceutical compositions for neuroprotection containing arylcyclohexylamines. These compositions comprise an arylcyclohexylamine in accordance with the formulas: ##STR1## in which: R.sup.1 represents ##STR2## with R.sup.4 being a hydrogen atom, a fluorine atom, an iodine atom or a methyl radical, R.sup.2 stands for a hydrogen atom, the radical OH or the radical CH.sub.3 and R.sup.3 stands for hydrogen atom or the radical CH.sub.2 R.sup.5 with R.sup.5 representing H, OH, Cl, Br or CH.sub.3 COO, provided that R.sup.2 and R.sup.3 are not both a hydrogen atom, or an addition salt to a pharmaceutically acceptable acid of said arylcyclohexylamine.